Evotec SE has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor antagonist eliapixant (BAY1817080), which stems from a former Evotec/Bayer multi-target research alliance.   Following a review of the available data, Bayer concluded that the overall benefit no longer outweighs the risk in the actively pursued indications.   As a consequence of Bayer’s decision, Evotec regains the rights to all P2X3 assets. The company will evaluat...